Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • North Dakota - United States Medical cannabis bill relating to hospice care signed by governor…
  • Lithuania THC to be banned in all tobacco products as of 1st April…
  • District of Columbia - United States Medical cannabis bill increasing access becomes law…
  • United States - Washington Interstate cannabis trade bill passes Senate and heads to House…
  • South Dakota - United States Governor vetoes industrial hemp revision bill…
  • South Dakota - United States Medical cannabis use prohibited if pregnant or breastfeeding…
  • South Dakota - United States Governor signs bill on medical cannabis qualifying conditions…
  • Oklahoma - United States Medical cannabis-related bill passes Senate…
  • Kentucky - United States Delta-8 THC bill signed by governor and becomes law…
  • Europe EC reveals environmental claims proposal…
  • Spain Parties rally behind Podemos proposal for hemp regulation…
  • Maryland - United States Personal use cannabis good, ‘volume dealing’ bad, House says…
View all
Blogs

What impact does the delay in voting on the MORE Act have on the CBD industry?

Written by || 25th September 2020 || Blogs | Policy and Politics | Regulation and legislation | North America United States

The Marijuana Opportunity Reinvestment and Expungement (MORE) Act was, of course, always more about cannabis than hemp-derived CBD specifically. And, as previously stated, its chances of passing were slim to none. ...

Restricted content. Do you want to read more?

Read our latest free content
Yellow card offence – but comments are a long way from being a dismissal of CBD
Mayhem in Mexico as agency grants firm hemp licence then vows to take it back
Relaxation beats intoxication – IHDC sales aren’t just about getting high
Spannabis: a celebration of the cannabis sector despite lingering uncertainties
Trulieve ends 2022 with over $1bn in revenue, 25 new dispensaries in the US
22nd Century’s cannabinoid division helps the company to double revenue

CannIntelligence.com provides independent, in-depth regulatory and market data and intelligence for the global cannabis and cannabinoid sector.

© 2023 Tamarind Media Limited (T/A CannIntelligence)
CannIntelligence does not provide legal, strategic or investment advice. Tamarind Media Limited, the publisher of CannIntelligence, does not accept any liability or responsibility for information or views published.